{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:00Z","timestamp":1791593820662,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T00:00:00Z","timestamp":1242000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Intravenous immunoglobulin (IVIg) is the first choice treatment for Guillain\u2010Barr\u00e9 syndrome (GBS). All patients initially receive the same arbitrary dose of 2g per kg body weight. Not all patients, however, show a good recovery after this standard dose. IVIg clearance may depend on disease severity and vary between individuals, implying that this dose is suboptimal for some patients. In this study, we determined whether the pharmacokinetics of IVIg is related to outcome in GBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 174 GBS patients who had previously participated in 2 randomized clinical trials. At entry, all patients were unable to walk unaided and received a standard dose of IVIg. Total IgG levels in serum samples obtained immediately before and 2 weeks after the start of IVIg administration were determined by turbidimetry and related to clinical outcome at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The increase in serum IgG (\u0394IgG) 2 weeks after IVIg treatment varied considerably between patients (mean, 7.8g\/L; standard deviation, 5.6g\/L). Patients with a low \u0394IgG recovered significantly more slowly, and fewer reached the ability to walk unaided at 6 months (log\u2010rank\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). In multivariate analysis adjusted for other known prognostic factors, a low \u0394IgG was independently associated with poor outcome (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>After a standard dose of IVIg treatment, GBS patients show a large variation in pharmacokinetics, which is related to clinical outcome. This may indicate that patients with a small increase in serum IgG level may benefit from a higher dosage or second course of IVIg. Ann Neurol 2009;66:597\u2013603<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ana.21737","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T10:43:25Z","timestamp":1242038605000},"page":"597-603","source":"Crossref","is-referenced-by-count":187,"title":["Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2010Barr\u00e9 syndrome"],"prefix":"10.1002","volume":"66","author":[{"given":"Krista","family":"Kuitwaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"de Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne P.","family":"Tio\u2010Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim C. J.","family":"Hop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert W.","family":"van Toorenenbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"CD001798","article-title":"Plasma exchange for Guillain\u2010Barr\u00e9 syndrome","volume":"2","author":"Rapha\u00ebl JC","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_3_2","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2010Barr\u00e9 syndrome","volume":"1","author":"Hughes RA","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-9-199705010-00008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.19.2367"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.12_suppl_6.S13"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.813"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.11.957"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)24050-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67665-9"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410090703"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92644-2"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70130-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2009.121"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00273538"},{"key":"e_1_2_6_21_2","first-page":"24","article-title":"Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial","volume":"112","author":"Cafiero F","year":"1992","journal-title":"Surgery"},{"key":"e_1_2_6_22_2","first-page":"1","article-title":"Metabolism of immunoglobulins","volume":"13","author":"Waldmann TA","year":"1969","journal-title":"Prog Allergy"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1993.1057"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400311"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02408.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.10.3136"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613331"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V90.10.3815","article-title":"IgG biosynthesis: no \u201cimmunoregulatory feedback.\u201d","volume":"90","author":"Junghans RP","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002109"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.2.235"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410304"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.35.8.1096"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.21737","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.21737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:49:37Z","timestamp":1697420977000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.21737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1002\/ana.21737"],"URL":"https:\/\/doi.org\/10.1002\/ana.21737","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1196963.1054054","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1196963.662061","asserted-by":"object"}]},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}